Last updated: March 13, 2026
What is the drug with NDC 33342-0200?
NDC 33342-0200 corresponds to Ozempic (semaglutide) injection, indicated for type 2 diabetes mellitus and chronic weight management. Approved by the FDA in 2017, Ozempic has gained significant market traction due to its efficacy and the expanding indications.
Market Size and Growth Drivers
Current Market Scope
- Global Diabetes Market (2022): Estimated at $88 billion, with an expected Compound Annual Growth Rate (CAGR) of 6% through 2028.[1]
- Semaglutide Market: Expected to reach $9.6 billion by 2028, from $3 billion in 2022, at a CAGR of 14.7%.[2]
Key Drivers
- Increasing prevalence of type 2 diabetes, with global cases surpassing 400 million in 2022.[3]
- Growing recognition of GLP-1 receptor agonists as first-line treatment.
- Expanded indication for weight management (Wegovy, Saxenda), boosting overall demand.
- Competitive landscape with Novo Nordisk (manufacturer of Ozempic and Wegovy) dominating.
Competitive Environment
- Major competitors include Eli Lilly’s Trulicity, AstraZeneca’s Bydureon, and emerging biosimilars.
- Patent expirations are unlikely before 2030, maintaining market exclusivity at current trend.
Pricing Landscape
Current Pricing (U.S.)
- List Price: Approximately $890 per 4-week supply (prescription, non-insurance).[4]
- Average Wholesale Price (AWP): Around $870–$900.
- Patient Out-of-Pocket: Varies; insurance typically covers 70-80%, leaving co-pay near $50–$150.
- Pricing Trends: Slight declines due to increased competition and biosimilars; however, high demand sustains premium pricing.
Reimbursement Policies
- Medicare Part D: Coverage varies; copayments depend on plan design.
- Commercial insurance: Similar coverage trends, with copays impacted by formulary tiers.
Future Price Projections
Short-term outlook (2023–2025)
- Expect minimal price decreases due to sustained demand and brand dominance.
- Biosimilar entry anticipated after 2029, which could lower prices by 20–30% upon market entry.
- Potential price reductions driven by value-based agreements and discounts negotiated with payers.
Long-term outlook (2026+)
- Biosimilar competition and patent cliffs could reduce list prices by 30–50%, aligning with trends seen in other biologics.
- Value-based pricing models may lead to individualized cost adjustments based on outcomes.
- Market saturation and generic-like biosimilar adoption could further pressure prices downward.
Key Opportunities and Risks
Opportunities
- Expansion into new markets, especially in Asia and Latin America, where diabetes prevalence is high.
- Launch of combination therapies and novel formulations.
- Continued collaborations with payers for managed access.
Risks
- Biosimilar and generic emergence erodes pricing power.
- Regulatory or reimbursement hurdles slow adoption.
- Potential shift in treatment guidelines favoring oral agents over injectable.
Summary Table
| Aspect |
Current State |
Short-term Projection |
Long-term Projection |
| Market Size |
$3 billion (semaglutide segment, 2022) |
$3.1–$3.3 billion (2023–2025) |
$4–$5 billion (2026+) |
| Pricing per 4-week supply |
~$890 |
Stable or slight decrease (~5%) |
10–30% decrease with biosimilar entry |
| Patent expiry |
Not yet expiring (2030+) |
No impact |
Major biosimilar competition expected |
Key Takeaways
- NDC 33342-0200, Ozempic, is a leading GLP-1 receptor agonist with robust market growth driven by diabetes prevalence and weight management uses.
- Current prices remain high but are trending downward marginally due to competition and biosimilar prospects.
- The market is expected to sustain growth until biosimilar entry, after which prices could decline significantly.
- Expansion into international markets presents growth potential but faces regulatory and reimbursement challenges.
- Value-based pricing and new formulations are future strategies to sustain revenue.
FAQs
1. When will biosimilars for semaglutide likely enter the market?
Biosimilars are projected to enter around 2029–2030, following patent expiry and regulatory approval timelines.
2. How do payer policies affect the actual price paid for Ozempic?
Payer negotiations and formulary positioning influence co-payments; prices can vary significantly based on insurance coverage.
3. What are the main competitors to Ozempic?
Trulicity (dulaglutide), Bydureon (exenatide), and the upcoming biosimilars for semaglutide.
4. What is the potential impact of weight management indications?
The addition of Wegovy, a higher-dose semaglutide, broadens market scope, potentially increasing overall revenues for the drug class.
5. Are there upcoming regulatory approvals affecting the market?
New indications for obesity and possibly combination therapies could expand market size, pending approval.
References
[1] Evaluate Pharma. (2022). Global Diabetes Market Overview.
[2] MarketsandMarkets. (2022). Semaglutide market forecast.
[3] International Diabetes Federation. (2022). Diabetes Atlas, 10th ed.
[4] GoodRx. (2023). Ozempic (semaglutide) Price and Coupons.
Note: Actual prices and projections are subject to change based on market dynamics, regulatory decisions, and patent filings.
